Evidence map›Paper›PMID 29322259›Full record

ArticleJournal of neurology2018

CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis.

Daniela Rossi, Paolo Volanti, Liliana Brambilla, Tiziana Colletti, Rossella Spataro, Vincenzo La Bella

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daniela RossiLaboratory for Research on Neurodegenerative Disorders, ICS Maugeri, 27100, Pavia, Italy.
Paolo VolantiALS Center and Neurorehabilitation Unit, ICS Maugeri, 98073, Mistretta, Italy.
Liliana BrambillaLaboratory for Research on Neurodegenerative Disorders, ICS Maugeri, 27100, Pavia, Italy.
Tiziana CollettiDepartment of Experimental BioMedicine and Clinical Neurosciences, ALS Clinical Research Center, University of Palermo, Via G La Loggia, 1, 90129, Palermo, Italy.
Rossella SpataroDepartment of Experimental BioMedicine and Clinical Neurosciences, ALS Clinical Research Center, University of Palermo, Via G La Loggia, 1, 90129, Palermo, Italy.
Vincenzo La BellaDepartment of Experimental BioMedicine and Clinical Neurosciences, ALS Clinical Research Center, University of Palermo, Via G La Loggia, 1, 90129, Palermo, Italy. vincenzo.labella@unipa.it.ORCID http://orcid.org/0000-0003-2045-1864
Istituti Clinici Scientifici Maugeri · ITUniversity of Palermo · IT

Funding

Italian Ministry of Health for the Ricerca Corrente NA
6 · The paper itself

Abstract

Elevated cerebrospinal fluid (CSF), Neurofilament Light (NF-L) and phosphorylated Heavy (pNF-H) chain levels have been found in Amyotrophic Lateral Sclerosis (ALS), with studies reporting a correlation of both neurofilaments (NFs) with the disease progression. Here, we measured NF-L and pNF-H concentrations in the CSF of ALS patients from a single tertiary Center and investigated their relationship with disease-related variables. A total of 190 ALS patients (Bulbar, 29.9%; Spinal, 70.1%; M/F = 1.53) and 130 controls with mixed neurological diseases were recruited. Demographic and clinical variables were recorded, and ΔFS was used to rate the disease progression. Controls were divided into two cohorts: (1) patients with non-inflammatory neurological diseases (CTL-1); (2) patients with acute/subacute inflammatory diseases and tumors, expected to lead to significant axonal and tissue damage (CTL-2). For each patient and control, CSF was taken at the time of the diagnostic work-up and stored following the published guidelines. CSF NF-L and pNF-H were assayed with commercially available ELISA-based methods. Standard curves (from independent ELISA kits) were highly reproducible for both NFs, with a coefficient of variation < 20%. We found that CSF NF-L and pNF-H levels in ALS were significantly increased when compared to CTL-1 (NF-L: ALS, 4.7 ng/ml vs CTL-1, 0.61 ng/ml, p < 0.001; pNF-H: ALS, 1.7 ng/ml vs CTL-1, 0.03 ng/ml, p < 0.0001), but not to CTL-2. Analysis of different clinical and prognostic variables disclosed meaningful correlations with both NF-L and pNF-H levels. Our results, from a relatively large ALS cohort, confirm that CSF NF-L and pNF-H represent valuable diagnostic and prognostic biomarkers in ALS.

Indexed as

AgedAmyotrophic Lateral SclerosisArea Under CurveBiomarkersDiagnosis, DifferentialDisease ProgressionEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInflammationKaplan-Meier EstimateMaleMiddle AgedNeurofilament ProteinsOligoclonal BandsBiomarkersneurofilament protein Hneurofilament protein LNeurofilament ProteinsOligoclonal BandsALSCSFDisease progressionNeurofilamentsNF-LpNF-H

Identifiers

PMID29322259
OpenAlexW2784297687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.